Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Article ID	Journal	Published Year	Pages	File Type
5658416	Gastroenterology	2017	50 Pages	PDF

Abstract

EAC cells become resistant to trastuzumab and pertuzumab by activating TGFÎ² signaling, which induces EMT. Agents that block TGFÎ² signaling can increase the anti-tumor efficacies of trastuzumab and pertuzumab.

Keywords

CSC PDX RTK Vimentin GSEA qRT-PCR Cancer stem cell (CSC)EAC miRs NSG FACS PBS VIM Patient-derived xenograft Esophageal adenocarcinoma epithelial to mesenchymal transition Biologic Transforming Growth Factor Beta Gene Set Enrichment Analysis EMT RTK, Receptor tyrosine kinase Targeted therapy microRNAs cancer stem cell Anti-tumor agent fluorescence-activated cell sorter Phosphate-buffered saline polymerase chain reaction PCR human epidermal growth factor receptor

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Authors

Eva A. Ebbing, Anne Steins, Evelyn Fessler, Phylicia Stathi, Willem Joost Lesterhuis, Kausilia K. Krishnadath, Louis Vermeulen, Jan Paul Medema, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven,